AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer
November 17-19, 2022
Hyatt Regency Austin
Timothy R. Rebbeck, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
Sangeeta N. Bhatia, Massachusetts Institute of Technology, Cambridge, Massachusetts
Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York
Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, Texas
Philip W. Kantoff, Convergent Therapeutics, Inc., Cambridge, Massachusetts
Douglas R. Lowy, National Cancer Institute, Bethesda, Maryland
Minetta C. Liu, Mayo Clinic College of Medicine and Science, Rochester, Minnesota
Prevention and early detection strategies have great potential to reduce the population burden of cancer. It has been estimated that 50-60% of cancers could be prevented if known strategies were optimally employed. This AACR Special Conference on Precision Prevention, Early Detection, and Interception of Cancer will raise the visibility of advances in the field of prevention and early detection that incorporate biological and mechanistic advances to inspire thinking about new approaches to cancer prevention. The conference will provide a forum for critically reviewing the evidence of the role of biological mechanisms in the cause and progression of cancer, highlighting knowledge of preneoplastic lesions, and new conceptual and technological advances in the field, and outlining the steps required to implement preventive and early detection measures. The program will not only bring together researchers and clinicians from diverse backgrounds to enhance cross-communication but will also spotlight talks from submitted abstracts to highlight the advancements and diversity of the cancer prevention and early detection research field.
AACR Statement Regarding Venues for the 2023 Annual Meeting and Other Conferences
The AACR released a statement regarding the venues for the 2023 Annual Meeting and its other conferences in response to recent legislative and political decisions at the state level that may not align with our values.Read the Statement
Delfi Diagnostics, Inc.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available